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ORIGINAL ARTICLE
Impact of baseline vitamin B12 status on the effect
of vitamin B12 supplementation on neurologic
function in older people: secondary analysis of data
from the OPEN randomised controlled trial
LM Miles1, E Allen1, R Clarke2, K Mills3, R Uauy1 and AD Dangour1
BACKGROUND/OBJECTIVES: The available evidence from randomised controlled trials suggests that vitamin B12
supplementation does not improve neurologic function in older people with marginal but not deﬁcient Vitamin B12 status. This
secondary analysis used data from the Older People and Enhanced Neurological function (OPEN) randomised controlled trial to
assess whether baseline vitamin B12 status or change in vitamin B12 status over 12 months altered the effectiveness of dietary
vitamin B12 supplementation on neurologic function in asymptomatic older people with depleted vitamin B12 status at study
entry.
SUBJECTS/METHODS: Vitamin B12 status was measured as serum concentrations of vitamin B12, holotranscobalamin,
homocysteine and via a composite indicator (cB12). Neurological function outcomes included eleven electrophysiological measures
of sensory and motor components of peripheral and central nerve function. Linear regression analyses were restricted to
participants randomised into the intervention arm of the OPEN trial (n= 91).
RESULTS: Analyses revealed an inconsistent pattern of moderate associations between some measures of baseline vitamin B12
status and some neurological responses to supplementation. The directions of effect varied and heterogeneity in effect across
outcomes could not be explained according to type of neurological outcome. There was no evidence of differences in the
neurological response to vitamin B12 supplementation according to change from baseline over 12 months in any indicator of B12
status.
CONCLUSIONS: This secondary analysis of high-quality data from the OPEN trial provides no evidence that baseline (or change
from baseline) vitamin B12 status modiﬁes the effect of vitamin B12 supplementation on peripheral or central nerve conduction
among older people with marginal vitamin B12 status. There is currently insufﬁcient evidence of efﬁcacy for neurological function
to support population-wide recommendations for vitamin B12 supplementation in healthy asymptomatic older people with
marginal vitamin B12 status.
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INTRODUCTION
Ageing is associated with a decline in vitamin B12 status, and
prevalence of vitamin B12 deﬁciency increases with age.1 As
dietary intakes are usually adequate in healthy populations,2 the
age-related decline in vitamin B12 status is usually attributed to
atrophic gastritis that reduces absorption of vitamin B12.3
Adequate vitamin B12 is necessary for optimal neurological
function. Symptoms of peripheral neuropathy associated with
vitamin B12 deﬁciency commonly include symmetric paresthesias,
numbness or gait problems, impaired position and cutaneous
sensation, impaired vibration sense and weakness.4,5
In the light of the high prevalence of preclinical deﬁciency,
routine vitamin B12 supplementation has been proposed in older
people.6,7 Indeed, US adults aged 450 years are advised to meet
their recommended daily allowance of 2.4 μg vitamin B12 per day
mainly by consuming either food fortiﬁed with vitamin B12 or a
vitamin B12-containing supplement.7 Yet surprisingly few
studies8–12 are available to help understand whether vitamin
B12 supplementation improves neurological function in older
people and overall, these studies (while heterogeneous in size,
effect and quality) do not suggest that there is strong evidence
that vitamin B12 supplementation improves neurologic function
in older people in the absence of frank vitamin B12 deﬁciency.
It is however possible that improvement in neurologic function
resulting from vitamin B12 supplementation may be apparent
only in non-deﬁcient people with the most marginal vitamin B12
status. For example, while primary analyses from the randomised
controlled trial (RCT) by Hvas et al.9 showed no difference in
neurologic outcomes between intervention (1 mg cyanocobala-
min administered intramuscularly weekly for 4 weeks) and control
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arms, there was evidence of effectiveness of treatment in
individuals with the lowest vitamin B12 status at study entry.
There is similar evidence to support greater beneﬁts of vitamin
B12 supplementation in people with the lowest vitamin B12 status
from studies on cognitive outcomes. The VITACOG RCT reported
that administering high doses of folic acid, vitamin B6 and vitamin
B12 over 2 years on measures of brain atrophy and several other
cognitive outcomes was more beneﬁcial in individuals with the
highest baseline plasma total homocysteine (tHcy) levels.13,14
The Older People and Enhanced Neurological function (OPEN)
RCT provides an opportunity to explore further, in a high-quality
data set, whether improvement in neurologic function from
vitamin B12 supplementation is limited to people with the lowest
baseline vitamin B12 status. The OPEN study was a double-blind
placebo-controlled RCT investigating the effects of 1 mg vitamin
B12 oral supplementation for 12 months on electrophysiological
indices of neurologic function in older people aged 75+ years with
marginal vitamin B12 status. The primary results from the trial
demonstrated no effect of vitamin B12 supplementation on any
measure of nerve function.11 This secondary analysis explores
whether differences in baseline vitamin B12 status or change in
vitamin B12 status over 12 months of intervention alters the
effectiveness of vitamin B12 supplementation on electrophysiolo-
gical indices of neurologic function in asymptomatic older people
with marginal vitamin B12 status at study entry.
METHODS
This study is a secondary analysis of data from the OPEN study,
the protocol of which has been published15 (www.isrctn.com;
ISRCTN54195799). Screening for participation in the OPEN study took
place between November 2008 and February 2010. Participants were aged
75+ years and recruited from 7 general practices in South East England.
Individuals with dementia, epilepsy, alcohol addiction, diabetes, pace-
makers or other implanted metallic devices, residents of nursing homes, or
a previous diagnosis of pernicious anaemia were excluded. Potential
participants with signiﬁcant cognitive impairment or who reported current
consumption of vitamin B12 supplements or who had received a vitamin
B12 injection in the previous 6 months were excluded. Individuals with
moderate vitamin B12 deﬁciency (serum vitamin B12 concentrations ⩾ 107
and o210 pmol/l (using a Beckman Coulter assay)) who did not have
anaemia (haemoglobin concentrations ⩾ 110 g/l for women and ⩾ 120 g/l
for men) were eligible to join the study.
Participants, who provided informed consent, were enroled in the trial
and randomised to treatment (n=99) or placebo arms (n= 102). Allocation
to treatment was balanced by age and sex, and all participants and
investigators were blind to treatment allocation. Allocated treatment
consisted of a single tablet containing 1 mg vitamin B12 (cyanocobalamin)
daily for 12 months. 91 participants in each arm of the trial provided
follow-up data on the OPEN trial primary outcome: posterior tibial
compound muscle action potential (CMAP) amplitude. The OPEN study
was designed to achieve 90% power to detect a ⩾ 28% difference in the
primary outcome (with 5% signiﬁcance) between arms of the trial.
At baseline and after 12 months follow-up, participants provided a blood
sample and undertook a series of neurophysiological function tests. Blood
samples were analysed for serum concentrations of vitamin B12 (using a
microbiologic assay); holotranscobalamin (holoTC; Axis-Shield radioimmu-
noassay; Axis-Shield plc) and tHcy (Abbott IMx analyzer; Abbott
Laboratories, Maidenhead, UK) in a single laboratory in Trinity College
Dublin. The microbiologic assay for vitamin B12 (used at study entry)
typically provides estimates of serum vitamin B12 concentration that are
~ 25% higher than those produced by the Beckman Coulter method (used
at initial screening). Median (and interquartile range) values for serum
vitamin B12 (estimated using the microbiologic assay by the same
laboratory in Trinity College Dublin) among older people in Ireland have
recently been published as 277 (216-369) pmol/l.16 88% of OPEN study
participants had vitamin B12 status below the median value for the
microbiologic assay reference standard (derived from a random sample of
470 from nationally representative adults in the Irish National Adult
Nutrition Survey; personal communication Dr Anne Molloy, 2013),
indicating that OPEN study participants had marginal vitamin B12 status
at study entry.
A single expert neurophysiologist (KM) conducted a battery of
peripheral nerve conduction tests and central motor conduction tests at
baseline and follow-up. Standard techniques were used involving surface
electrodes. Skin temperature of the dorsum of the foot and hand was
measured to allow for appropriate adjustments in the analyses because
nerve conduction in peripheral nerves is sensitive to temperature of the
limbs.17 Posterior tibial CMAP amplitude evoked by distal stimulation was
the primary trial outcome. The seven secondary peripheral nerve outcomes
were common peroneal CMAP amplitude (also evoked by distal
stimulation); posterior tibial and common peroneal conduction velocities
measured by recording from the adductor hallucis (AH) and extensor
digitorum brevis muscles respectively; and sensory action potential (SAP)
amplitude (maximum deviation of the electrical response) and conduction
velocity measured in the sural and superﬁcial peroneal nerves. Together
these outcomes represent each component of peripheral nerve function:
posterior tibial and common peroneal CMAP reﬂects the number of motor
axons that can be accessed by an electrical stimulus which in turn reﬂects
muscle strength;18,19 sural and superﬁcial peroneal SAP amplitudes are
indices of nerve ﬁbre number; and sensory (sural and superﬁcial peroneal
nerve) or motor (posterior tibial and common peroneal) conduction
velocity is an indicator of myelination.20 All nerve conduction outcomes
were measured on the right side of the body.
Central motor conduction tests were measured using transcranial
magnetic stimulation, which painlessly and noninvasively excites the
motor cortex.21 Further secondary outcomes were mean abductor digiti
motor (ADM), motor evoked potential (MEP) amplitude, and ADM and AH
central motor conduction time (CMCT). With the right ADMmuscle partially
activated voluntarily, stimuli were delivered to evoke MEPs, and mean
amplitudes were measured. Similarly, the leg area of motor cortex was
excited to measure MEPs evoked in the AH muscle. ADM and AH CMCT
were calculated by subtracting the time to response in each muscle from
an estimate of the peripheral nerve conduction time.
Vitamin B12 and holoTC were used as measures of vitamin B12 status. In
addition, cB12 was used as a composite indicator of vitamin B12 status
combining vitamin B12, holoTC and tHcy.22 Although tHcy alone does not
have good speciﬁcity as an indicator of vitamin B12 status, it is also
included as an indicator of vitamin B12 in this study for exploratory
purposes.
Statistical analysis
Secondary analyses were performed to explore whether baseline or
change in vitamin B12 status altered the impact of dietary vitamin B12
supplementation on neurologic function. Analyses were restricted to the
intervention arm (n= 91), because the placebo arm did not receive any
vitamin B12 supplementation and accordingly, change in vitamin B12
status was negligible,11 and minor changes in nerve conduction were
assumed to be due to variability in repeated measures. Analyses were
exploratory in nature and aimed to identify consistent patterns in ﬁndings
rather than applying stringent P-values to test for statistical signiﬁcance.
The effects of supplementation on vitamin B12 status according to
baseline status were explored by baseline quartiles of vitamin B12, holoTC,
tHcy and cB12 as indicators of vitamin B12 status. Linear regression models
were used to test for associations between baseline and change in vitamin
B12 status (measured by vitamin B12, holoTC, tHcy and cB12) and
neurologic response to vitamin B12 supplementation. Eleven nerve
conduction outcomes were used, consistent with the outcomes used in
the primary analyses from the OPEN study.11 For each nerve conduction
outcome, linear regression models tested for associations between
baseline vitamin B12 status and change in the outcome (in response to
supplementation), adjusted for the corresponding baseline measure of
nerve conduction, age, sex and change in skin temperature. Similarly,
linear regression models tested for associations between change in
vitamin B12 status and change in the outcome (in response to
supplementation) for the same nerve conduction outcomes; adjustments
included baseline measures of vitamin B12 in addition to those listed
above. All linear regression models were boot-strapped to allow for non-
normal distributions of exposures and outcomes. Results are presented as
mean change in outcome with bias-corrected 95% conﬁdence intervals.
Because the analyses involved multiple comparisons, P-values have been
interpreted with caution. Statistical analyses were conducted using STATA
(version 14 StataCorp, TX, USA).
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Ethics
The OPEN study was reviewed and approved by the National Research Ethics
Committee (08/H0305/18) and the London School of Hygiene & Tropical
Medicine Ethics Committee (LSHTM; no. 5298). The secondary analyses
presented here were approved by the LSHTM Ethics Committee (no. 7176).
RESULTS
Participants included in the current analysis had a mean age of
79.9 years and 46.5% were male. Comparing baseline with
12 months, oral supplementation was effective in increasing
vitamin B12 status: vitamin B12, holoTC and cB12 increased (mean
change 409.6 pmol/l, 184.3 pmol/l and 1.5 respectively) and tHcy
(mean change − 2.8 μmol/l) decreased at 12 month follow-up
(Table 1). Levels of vitamin B12 and cB12 at follow-up were
constant across quartiles of baseline status (vitamin B12: F test
P= 0.44; cB12: F test P= 0.21), suggesting a plateau effect
(Figure 1). In contrast, the effect of vitamin B12 supplementation
on tHcy and holoTC differed across baseline quartiles (tHcy: test
for trend Po0.001; holoTC: test for trend P= 0.01).
Linear regression models found no evidence of a difference in
impact of vitamin B12 supplementation on the primary trial
outcome (posterior tibial CMAP amplitude; Table 2). For the other
nerve function outcomes, effect sizes were generally small and
patterns of effect inconsistent. There was evidence of an association
of baseline vitamin B12 status with common peroneal CMAP
amplitude, with higher baseline vitamin B12 being associated with a
smaller change in common peroneal CMAP amplitude in response
to supplementation (β=− 0.01 (−0.01 to −0.00), P=0.02; P40.05 for
all other measures of vitamin B12 status).
There was evidence of inverse associations of baseline vitamin
B12 and cB12 with change in tibial motor conduction velocity;
participants with the lowest baseline status tended to have a
greater change in motor conduction velocity in response to
supplementation over 12 months. In contrast, weak associations
were detected between baseline holoTC and cB12, and change
in common peroneal motor conduction velocity in response
to supplementation that suggest a greater change in motor
conduction velocity with a higher baseline status. There was also
evidence of a positive association of baseline vitamin B12 status
with and a greater change in sensory sural conduction velocity in
response to supplementation (β= 0.02 (0.00 to 0.03), P= 0.05;
P40.05 for all other measures of vitamin B12 status).
In measure of central nerve conduction, vitamin B12 supple-
mentation improved (that is, decreases) AH CMCT in participants
with lower baseline cB12 status (β= 2.19 (0.10 to 4.04), P= 0.03).
Results for change in ADM CMCT were consistent in direction of
effect but smaller in magnitude and not statistically signiﬁcant
(β= 0.53 (−0.75 to 1.43), P= 0.31). In contrast, results for mean
ADM MEP amplitude suggest that a greater response was
observed in participants with higher baseline vitamin B12 status
(as measured by tHcy and cB12).
Linear regression analyses show that neurologic response
to vitamin B12 supplementation did not differ by change in
vitamin B12 status (Table 3). Null results are consistent across each
measure of vitamin B12 status and all nerve conduction outcomes.
DISCUSSION
Key ﬁndings
The secondary analyses presented here used high-quality data
from the OPEN RCT to explore the relevance of baseline (or
change from baseline) vitamin B12 status on the effectiveness of
vitamin B12 supplementation for neurological function in older
people with marginal vitamin B12 status. The analysis did not
identify an impact of baseline (or change from baseline) vitamin
B12 status on the effect of vitamin B12 supplementation on the
OPEN trial primary outcome (tibial CMAP amplitude). When T
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considering secondary neurological outcomes, analyses using
some indicators of vitamin B12 status (but not others) revealed
suggestive evidence of associations between baseline vitamin B12
status and some peripheral and central neurologic responses to
supplementation. However, directions of effect were inconsistent:
an equal number of analyses showed suggestive evidence of
greater neurologic improvement in response to supplementation
in participants with higher baseline vitamin B12 status as there
were analyses showing suggestive evidence of greater neurologic
improvement in response to supplementation in participants with
lower baseline vitamin B12 status. Heterogeneity in ﬁndings across
neurologic outcomes could not be explained by the aspect of
neurologic function each outcomes measured: there were no
differences in ﬁndings in peripheral versus central nerve conduc-
tion; motor versus sensory peripheral nerve conduction; or
conduction velocities versus CMAP or SAP amplitudes. Taken
together, this secondary analysis of OPEN trial data suggests that
there is no evidence of differences in the effect of vitamin B12
supplementation on measures of nerve conduction based on
baseline vitamin B12 status (vitamin B12, holoTC, tHcy or cB12).
This analysis also found no evidence of difference in neurologic
response to vitamin B12 supplementation according to any
indicator of change in vitamin B12 status.
Comparison with other studies
Whilst previous reports9 suggested that individuals with the
lowest vitamin B12 status might beneﬁt most from an
intramuscular vitamin B12 intervention in terms of neurological
symptoms, results from this study indicate that this does not
extend to beneﬁts of an oral vitamin B12 intervention or
improvements in nerve conduction. This study also extends the
primary ﬁndings of the OPEN RCT11 by exploring whether the null
ﬁndings of the intervention might be attributed to the relatively
replete vitamin B12 status of participants. As the secondary
analyses found no consistent evidence of a greater beneﬁt of
vitamin B12 supplementation in terms of neurologic function in
those with the lowest vitamin B12 status, it remains unlikely that
the OPEN trial intervention would have been effective if
participants had poorer vitamin B12 status at baseline alongside
absence of neurologic or haematological symptoms of deﬁciency.
Strengths and weaknesses
The use of several measures of vitamin B12 status and
measurement of neurologic function by nerve conduction are
strengths of the study. In particular, holoTC measures the active
fraction of vitamin B12 and has been proposed as appropriate to
use in the subclinical situation.23,24 The use of cB12 has the
advantage of combining biomarkers of circulating vitamin B12
and a functional biomarker of vitamin B12 status.22 Poor renal
function can be a cause of elevated tHcy6 and is also reported to
be associated with cB1225 but was not measured in the OPEN
study. Nerve conduction tests use state-of-the-art methods and
are objective measures. All baseline and follow-up testing was
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Figure 1. Vitamin B12 status by quartile of serum vitamin B12,1 holotranscobalamin,2 homocysteine3 and a composite indicator
(cB12) in the study population (n= 91) of older people in the intervention arm of the OPEN study at baseline (0 months) and follow-up
(12 months).
Impact of baseline vitamin B12 status
LM Miles et al
4
European Journal of Clinical Nutrition (2017) 1 – 7 © 2017 Macmillan Publishers Limited, part of Springer Nature.
conducted by a single neurophysiologist thereby eliminating
inter-observer variability.
It is recognised that this secondary analysis is limited in
statistical power. It is possible that trends would have been more
easily detected in a larger study. It is also possible that the
statistically signiﬁcant associations detected in this study were
identiﬁed by chance as a result of multiple comparisons across
several outcomes. Furthermore, it remains possible that the
duration of the vitamin B12 supplementation was too short and
that beneﬁts of supplementation only become evident after
several years of treatment.
Policy relevance and research needs
This secondary analysis of the OPEN trial does not provide
evidence to suggest that oral supplementation with vitamin B12
has beneﬁcial effects on neurological function in individuals with
marginal vitamin B12 status. While prevention of vitamin B12
deﬁciency remains important, especially in older people, the
available evidence does not support population-wide screening
for moderate vitamin B12 deﬁciency in the absence of anaemia or
neurological symptoms, nor population-wide recommendations
for vitamin B12 supplementation in healthy asymptomatic older
people. Treatment for neurological impairment attributed to
Table 2. Linear regression analyses to assess relationship between baseline vitamin B12 status and change in nerve conduction in response to
supplementationa
Change in outcome Baseline B12 (pmol/l) Baseline holoTC (pmol/l) Baseline tHcy (μmol/l) Baseline cB12
Motor tibial CMAP amplitude (mV) n 73b 70b 72b 70b
β − 0.00 (−0.01 to 0.00) 0.01 (−0.01 to 0.03) 0.04 (−0.03 to 0.15) − 0.12 (−1.21 to 1.01)
P 0.45 0.42 0.32 0.84
Motor common peroneal CMAP amplitude (mV) n 71c 69d 70c 69d
β − 0.01 (−0.01 to − 0.00) 0.00 (−0.01 to 0.01) − 0.00 (−0.06 to 0.08) − 0.02 (−0.81 to 0.83)
P 0.02 0.94 0.97 0.97
Motor tibial conduction velocity (m/s) n 72 69 71 69
β − 0.02 (−0.04 to − 0.01) − 0.02 (−0.06 to 0.03) 0.11 (−0.09 to 0.27) − 2.12 (−4.40 to 0.34)
P 0.01 0.40 0.21 0.08
Motor common peroneal conduction velocity (m/s) n 71 69 70 69
β 0.00 (−0.01 to 0.02) 0.04 (0.00 to 0.09) − 0.11 (−0.25 to 0.14) 2.05 (−0.28 to 4.21)
P 0.75 0.04 0.25 0.07
Sensory sural SAP amplitude (μV) n 59e 58f 59g 58f
β − 0.01 (−0.04 to 0.00) − 0.01 (−0.04 to 0.03) 0.09 (−0.04 to 0.21) − 1.03 (−3.09 to 0.59)
P 0.23 0.64 0.15 0.27
Sensory superﬁcial peroneal SAP amplitude (μV) n 49h 48i 49j 48i
β − 0.00 (−0.01 to 0.02) − 0.00 (−0.07 to 0.03) 0.07 (−0.26 to 0.37) − 0.81 (−4.50 to 1.84)
P 0.85 0.85 0.66 0.61
Sensory sural conduction velocity (m/s) n 59 58 59 58
β 0.02 (0.00 to 0.03) 0.03 (−0.02 to 0.07) 0.03 (−0.16 to 0.30) 1.81 (−0.96 to 4.35)
P 0.05 0.18 0.82 0.17
Sensory superﬁcial peroneal conduction velocity (m/s) n 49 48 49 48
β − 0.00 (−0.03 to 0.03) − 0.02 (−0.11 to 0.07) 0.17 (−0.15 to 0.62) − 1.58 (−7.07 to 3.25)
P 0.83 0.62 0.38 0.54
ADM CMCT (ms) n 72 69 71 69
β 0.00 (−0.00 to 0.01)k 0.01 (−0.01 to 0.03)k − 0.00 (−0.08 to 0.09)k 0.53 (−0.75 to 1.43)k
P 0.77k 0.21k 0.98k 0.31k
AH CMCT (ms) n 66 63 65 63
β 0.00 (−0.01 to 0.02) 0.03 (−0.01 to 0.06) − 0.07 (−0.20 to 0.08) 2.19 (0.10 to 4.04)
P 0.77 0.12 0.35 0.03
Mean ADM MEP amplitude (mV) n 74 71 73 71
β 0.00 (−0.00 to 0.01)k 0.00 (−0.01 to 0.01)k − 0.07 (−0.13 to − 0.03)k 0.72 (0.04 to 1.29)k
P 0.17k 0.33k 0.00k 0.03k
Abbreviations: ADM, abductor digiti motor; AH, adductor hallucis; CMAP, compound muscle action potential; CMCT, central motor conduction time; holoTC,
holotranscobalamin; MEP, motor evoked potential; SAP, sensory action potential; tHcy, total homocysteine. aAdjusted for baseline measure of the neurologic
outcome, baseline age, baseline sex and change in skin temperature (foot), unless otherwise stated. bThree subjects with 0 values for tibial CMAP amplitude at
baseline or follow-up excluded. cFive subjects with 0 values for common peroneal CMAP amplitude at baseline or follow-up excluded. dFour subjects with 0
values for common peroneal CMAP amplitude at baseline or follow-up excluded. eSeventeen subjects with 0 values for sural SAP amplitude at baseline or
follow-up excluded; 8 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up; and 3 of these had
undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. fFifteen subjects with 0 values for sural SAP amplitude at
baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up; and 3 of
these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. gSixteen subjects with 0 values for sural SAP
amplitude at baseline or follow-up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up;
and 3 of these had undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. hTwenty-seven subjects with 0 values for
superﬁcial peroneal SAP amplitude at baseline or follow-up excluded; 11 of these had detectable superﬁcial peroneal SAP amplitude at baseline and no
detectable (0) superﬁcial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superﬁcial peroneal SAP amplitude at baseline and
detectable superﬁcial peroneal SAP amplitude at follow-up. iTwenty-ﬁve subjects with 0 values for superﬁcial peroneal SAP amplitude at baseline or follow-up
excluded; 10 of these had detectable superﬁcial peroneal SAP amplitude at baseline and no detectable (0) superﬁcial peroneal SAP amplitude at follow-up;
and 9 of these had undetectable (0) superﬁcial peroneal SAP amplitude at baseline and detectable superﬁcial peroneal SAP amplitude at follow-up. jTwenty-six
subjects with 0 values for superﬁcial peroneal SAP amplitude at baseline or follow-up excluded; 10 of these had detectable superﬁcial peroneal SAP amplitude
at baseline and no detectable (0) superﬁcial peroneal SAP amplitude at follow-up; and 10 of these had undetectable (0) superﬁcial peroneal SAP amplitude at
baseline and detectable superﬁcial peroneal SAP amplitude at follow-up. kAdjusted for baseline measure of the neurologic outcome, baseline age, baseline sex
and change in skin temperature (hand).
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vitamin B12 deﬁciency should be managed as appropriate by
clinicians, rather than handled at the population level.
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Table 3. Linear regression analyses to assess relationship between change in vitamin B12 status and change in nerve conduction in response to
supplementationa
Change in outcome Change in B12 C (pmol/l) Change in holoTC (pmol/l) Change in tHcy (μmol/l) Change in cB12
Motor tibial CMAP amplitude (mV) n 71b 68b 70b 68b
β 0.00 (−0.00 to 0.00) 0.00 (−0.00 to 0.01) − 0.07 (−0.22 to 0.08) 0.71 (−0.36 to 1.91)
P 0.41 0.38 0.34 0.22
Motor common peroneal CMAP amplitude (mV) n 69c 67d 68c 67d
β 0.00 (−0.00 to 0.00) 0.00 (−0.00 to 0.00) 0.10 (−0.12 to 0.34) 0.52 (−0.14 to 1.39)
P 0.98 0.31 0.41 0.18
Motor tibial conduction velocity (m/s) n 70 67 69 67
β 0.00 (−0.00 to 0.00) 0.00 (−0.00 to 0.01) − 0.07 (−0.59 to 0.43) 0.72 (−1.50 to 3.35)
P 0.98 0.52 0.77 0.57
Motor common peroneal conduction velocity (m/s) n 69 67 68 67
β − 0.00 (−0.00 to 0.00) − 0.00 (−0.01 to 0.00) 0.10 (−0.39 to 0.78) 0.24 (−1.70 to 2.46)
P 0.81 0.35 0.75 0.82
Sensory sural SAP amplitude (μV) n 58e 57f 58g 57f
β − 0.00 (−0.00 to 0.00) 0.00 (−0.01 to 0.01) − 0.13 (−0.56 to 0.22) 0.23 (−1.62 to 2.59)
P 0.93 0.98 0.51 0.82
Sensory superﬁcial peroneal SAP amplitude (μV) n 49h 48i 49j 48i
β 0.00 (−0.00 to 0.01) 0.00 (−0.01 to 0.02) − 0.37 (−1.08 to -0.00) 2.45 (−0.52 to 7.40)
P 0.66 0.69 0.15 0.19
Sensory sural conduction velocity (m/s) n 58 57 58 57
β 0.00 (−0.00 to 0.01) 0.00 (−0.01 to 0.01) 0.29 (−0.21 to 0.82) 0.94 (−2.43 to 3.23)
P 0.05 0.64 0.25 0.51
Sensory superﬁcial peroneal conduction velocity (m/s) n 49 48 49 48
β − 0.01 (−0.02 to 0.01) − 0.01 (−0.03 to 0.01) − 0.18 (−0.82 to 0.74) − 1.64 (−7.42 to 3.01)
P 0.37 0.32 0.65 0.54
ADM CMCT (ms) n 70 67 69 67
β − 0.00 (−0.00 to 0.00)k − 0.00 (−0.00 to 0.00)k 0.02 (−0.19 to 0.17)k − 0.19 (−1.01 to 0.90)k
P 0.15k 0.35k 0.81k 0.68k
AH CMCT (ms) n 64 61 63 61
β 0.00 (−0.00 to 0.00) 0.00 (−0.01 to 0.01) 0.18 (−0.22 to 0.66) 0.42 (−1.53 to 2.02)
P 0.41 0.84 0.42 0.64
Mean ADM MEP amplitude (mV) n 72 69 71 69
β 0.00 (−0.00 to 0.00)k 0.00 (−0.00 to 0.00)k −0.03 (−0.13 to 0.07)k 0.50 (−0.27 to 1.23)k
P 0.36k 0.72k 0.52k 0.19k
Abbreviations: ADM, abductor digiti motor; AH, adductor hallucis; CMAP, compound muscle action potential; CMCT, central motor conduction time; holoTC,
holotranscobalamin; MEP, motor evoked potential; SAP, sensory action potential; tHcy, total homocysteine. aAdjusted for baseline measure of neurologic
outcome, baseline B12/holoTC/tHcy/cB12 status, baseline age, baseline sex and change in skin temperature (foot) unless otherwise stated. bThree subjects
with 0 values for tibial CMAP at baseline or follow-up excluded. cFive subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded.
dFour subjects with 0 values for common peroneal CMAP at baseline or follow-up excluded. eSixteen subjects with 0 values for sural SAP at baseline or follow-
up excluded; 7 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up; and 3 of these had
undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. fFourteen subjects with 0 values for sural SAP at baseline or
follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up; and 3 of these had
undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. gFifteen subjects with 0 values for sural SAP at baseline or
follow-up excluded; 6 of these had detectable sural SAP amplitude at baseline and no detectable (0) sural SAP amplitude at follow-up; and 3 of these had
undetectable (0) sural SAP amplitude at baseline and detectable sural SAP amplitude at follow-up. hTwenty-ﬁve subjects with 0 values for superﬁcial peroneal
SAP at baseline or follow-up excluded; 10 of these had detectable superﬁcial peroneal SAP amplitude at baseline and no detectable (0) superﬁcial peroneal
SAP amplitude at follow-up; and 9 of these had undetectable (0) superﬁcial peroneal SAP amplitude at baseline and detectable superﬁcial peroneal SAP
amplitude at follow-up. iTwenty-three subjects with 0 values for superﬁcial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable
superﬁcial peroneal SAP amplitude at baseline and no detectable (0) superﬁcial peroneal SAP amplitude at follow-up; and 8 of these had undetectable
(0) superﬁcial peroneal SAP amplitude at baseline and detectable superﬁcial peroneal SAP amplitude at follow-up. jTwenty-four subjects with 0 values for
superﬁcial peroneal SAP at baseline or follow-up excluded; 9 of these had detectable superﬁcial peroneal SAP amplitude at baseline and no detectable
(0) superﬁcial peroneal SAP amplitude at follow-up; and 9 of these had undetectable (0) superﬁcial peroneal SAP amplitude at baseline and detectable
superﬁcial peroneal SAP amplitude at follow-up. kAdjusted for baseline measure of neurologic outcome, baseline B12/holoTC/tHcy/cB12 status, baseline age,
baseline sex and change in skin temperature (hand).
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